Skip to main content
Erschienen in: Breast Cancer Research and Treatment 3/2019

09.11.2018 | Epidemiology

Concordance with BRCA1/2 testing guidelines among women in The Health of Women (HOW) Study®

verfasst von: Michelle I. Silver, William Klein, Goli Samimi, Lori Minasian, Jennifer Loud, Megan C. Roberts

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To evaluate factors associated with compliance to the National Comprehensive Cancer Network (NCCN) guidelines for BRCA1/2 testing and identify groups who are at risk of under- and over-use of BRCA1/2 testing.

Methods

Data included 20,758 women from Dr. Susan Love Research Foundation’s The Health of Women (HOW) Study®. Multinomial logistic regression was used to examine the association of socioeconomic and demographic characteristics with whether the woman was over-, under-, or appropriately tested for BRCA1/2 mutations, per 2015 NCCN guidelines.

Results

3894 women (18.8%) reported BRCA1/2 testing. 5628 (27.1%) women who met NCCN criteria for testing were not tested. Among women with a history of breast cancer, those without health insurance were more likely to be under-tested (OR 2.04, 95% CI 1.15–3.60) than those with managed care insurance, and higher education was associated with a lower likelihood of under-testing (Graduate/professional degree OR 0.71, 95% CI 0.55–0.91).

Conclusion

Almost 30% of women were under-tested, indicating that many high-risk women who may benefit from genetic testing are currently being missed. Without appropriate testing, providers are unable to tailor screening recommendations to those carrying mutations who are at highest risk. Patient and healthcare provider education and outreach targeted to low-income and under-served populations may assist in reducing under-testing.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Howlader NNA, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (2015) SEER cancer statistics review, 1975–2012, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2012/, based on November 2014 SEER data submission, posted to the SEER web site, April 2015 Howlader NNA, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (2015) SEER cancer statistics review, 1975–2012, National Cancer Institute. Bethesda, MD, http://​seer.​cancer.​gov/​csr/​1975_​2012/​, based on November 2014 SEER data submission, posted to the SEER web site, April 2015
2.
Zurück zum Zitat Siu AL (2016) Screening for breast cancer: U.S. preventive services task force recommendation statementscreening for breast cancer. Ann Intern Med 164(4):279–296CrossRefPubMed Siu AL (2016) Screening for breast cancer: U.S. preventive services task force recommendation statementscreening for breast cancer. Ann Intern Med 164(4):279–296CrossRefPubMed
3.
Zurück zum Zitat Moyer VA (2014) Risk assessment, genetic counseling, and genetic testing for brca-related cancer in women: U.S. preventive services task force recommendation statement. Ann Intern Med 160(4):271–281CrossRefPubMed Moyer VA (2014) Risk assessment, genetic counseling, and genetic testing for brca-related cancer in women: U.S. preventive services task force recommendation statement. Ann Intern Med 160(4):271–281CrossRefPubMed
4.
Zurück zum Zitat Bevers TB, Anderson BO, Bonaccio E, Buys S, Daly MB, Dempsey PJ, Farrar WB, Fleming I, Garber JE, Harris RE et al (2009) Breast cancer screening and diagnosis. J Natl Compr Cancer Netw 7(10):1060–1096CrossRef Bevers TB, Anderson BO, Bonaccio E, Buys S, Daly MB, Dempsey PJ, Farrar WB, Fleming I, Garber JE, Harris RE et al (2009) Breast cancer screening and diagnosis. J Natl Compr Cancer Netw 7(10):1060–1096CrossRef
5.
Zurück zum Zitat ACOG Practice Bulletin No (2009) 103: Hereditary breast and ovarian cancer syndrome. Obstet Gynecol 113(4):957–966CrossRef ACOG Practice Bulletin No (2009) 103: Hereditary breast and ovarian cancer syndrome. Obstet Gynecol 113(4):957–966CrossRef
7.
Zurück zum Zitat Lee MV, Katabathina VS, Bowerson ML, Mityul MI, Shetty AS, Elsayes KM, Balachandran A, Bhosale PR, McCullough AE, Menias CO: BRCA-associated cancers: role of imaging in screening, diagnosis, and management. RadioGraphics 2017, 37(4):1005–1023CrossRefPubMed Lee MV, Katabathina VS, Bowerson ML, Mityul MI, Shetty AS, Elsayes KM, Balachandran A, Bhosale PR, McCullough AE, Menias CO: BRCA-associated cancers: role of imaging in screening, diagnosis, and management. RadioGraphics 2017, 37(4):1005–1023CrossRefPubMed
9.
Zurück zum Zitat Antoniou A, Pharoah PDP, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg Å et al (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72(5):1117–1130CrossRefPubMedPubMedCentral Antoniou A, Pharoah PDP, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg Å et al (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72(5):1117–1130CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Network NCC (2015) Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women. In: National Comprehensive Cancer Network, vol. 2 Network NCC (2015) Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women. In: National Comprehensive Cancer Network, vol. 2
12.
Zurück zum Zitat Anderson K, Jacobson JS, Heitjan DF, Zivin JG, Hershman D, Neugut AI, Grann VR (2006) Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation. Ann Intern Med 144(6):397–406CrossRefPubMed Anderson K, Jacobson JS, Heitjan DF, Zivin JG, Hershman D, Neugut AI, Grann VR (2006) Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation. Ann Intern Med 144(6):397–406CrossRefPubMed
13.
Zurück zum Zitat Force USPST (2005) Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement. Ann Intern Med 143(5):355–361CrossRef Force USPST (2005) Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement. Ann Intern Med 143(5):355–361CrossRef
14.
Zurück zum Zitat Ozanne E, Cipriano L, Cameron M, Newman T, Esserman L (2009) Cost-effectiveness of genetic testing for BRCA1 and BRCA2 mutations. Can Res 69(2 Supplement):6100CrossRef Ozanne E, Cipriano L, Cameron M, Newman T, Esserman L (2009) Cost-effectiveness of genetic testing for BRCA1 and BRCA2 mutations. Can Res 69(2 Supplement):6100CrossRef
15.
Zurück zum Zitat Levy DE, Garber JE, Shields AE (2009) Guidelines for genetic risk assessment of hereditary breast and ovarian cancer: early disagreements and low utilization. J Gen Intern Med 24(7):822–828CrossRefPubMedPubMedCentral Levy DE, Garber JE, Shields AE (2009) Guidelines for genetic risk assessment of hereditary breast and ovarian cancer: early disagreements and low utilization. J Gen Intern Med 24(7):822–828CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Childers CP, Childers KK, Maggard-Gibbons M, Macinko J: National estimates of genetic testing in women with a history of breast or ovarian cancer. J Clin Oncol 2017, 35(34), 3800–3806CrossRef Childers CP, Childers KK, Maggard-Gibbons M, Macinko J: National estimates of genetic testing in women with a history of breast or ovarian cancer. J Clin Oncol 2017, 35(34), 3800–3806CrossRef
17.
Zurück zum Zitat Armstrong J, Toscano M, Kotchko N, Friedman S, Schwartz MD, Virgo KS, Lynch K, Andrews JE, Aguado Loi CX, Bauer JE et al (2015) Utilization and outcomes of BRCA genetic testing and counseling in a national commercially insured population: the ABOUT study. JAMA Oncol 1(9):1251–1260CrossRefPubMed Armstrong J, Toscano M, Kotchko N, Friedman S, Schwartz MD, Virgo KS, Lynch K, Andrews JE, Aguado Loi CX, Bauer JE et al (2015) Utilization and outcomes of BRCA genetic testing and counseling in a national commercially insured population: the ABOUT study. JAMA Oncol 1(9):1251–1260CrossRefPubMed
18.
Zurück zum Zitat Weldon CB, Trosman JR, Gradishar WJ, Benson AB III, Schink JC (2012) Barriers to the use of personalized medicine in breast cancer. J Oncol Pract 8(4):e24–e31CrossRefPubMedPubMedCentral Weldon CB, Trosman JR, Gradishar WJ, Benson AB III, Schink JC (2012) Barriers to the use of personalized medicine in breast cancer. J Oncol Pract 8(4):e24–e31CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Borzekowski DL, Guan Y, Smith KC, Erby LH, Roter DL (2014) The Angelina effect: immediate reach, grasp, and impact of going public. Genet Med 16(7):516–521CrossRefPubMed Borzekowski DL, Guan Y, Smith KC, Erby LH, Roter DL (2014) The Angelina effect: immediate reach, grasp, and impact of going public. Genet Med 16(7):516–521CrossRefPubMed
20.
Zurück zum Zitat Juthe RH, Zaharchuk A, Wang C (2015) Celebrity disclosures and information seeking: the case of Angelina Jolie. Genet Med 17(7):545–553CrossRefPubMed Juthe RH, Zaharchuk A, Wang C (2015) Celebrity disclosures and information seeking: the case of Angelina Jolie. Genet Med 17(7):545–553CrossRefPubMed
21.
Zurück zum Zitat Lebo PB, Quehenberger F, Kamolz LP, Lumenta DB (2015) The Angelina effect revisited: exploring a media-related impact on public awareness. Cancer 121(22):3959–3964CrossRefPubMed Lebo PB, Quehenberger F, Kamolz LP, Lumenta DB (2015) The Angelina effect revisited: exploring a media-related impact on public awareness. Cancer 121(22):3959–3964CrossRefPubMed
22.
Zurück zum Zitat Noar SM, Althouse BM, Ayers JW, Francis DB, Ribisl KM (2015) Cancer information seeking in the digital age: effects of Angelina Jolie’s prophylactic mastectomy announcement. Med Decis Mak 35(1):16–21CrossRef Noar SM, Althouse BM, Ayers JW, Francis DB, Ribisl KM (2015) Cancer information seeking in the digital age: effects of Angelina Jolie’s prophylactic mastectomy announcement. Med Decis Mak 35(1):16–21CrossRef
23.
Zurück zum Zitat Evans DG, Barwell J, Eccles DM, Collins A, Izatt L, Jacobs C, Donaldson A, Brady AF, Cuthbert A, Harrison R et al (2014) The Angelina Jolie effect: how high celebrity profile can have a major impact on provision of cancer related services. Breast Cancer Res 16(5):442CrossRefPubMedPubMedCentral Evans DG, Barwell J, Eccles DM, Collins A, Izatt L, Jacobs C, Donaldson A, Brady AF, Cuthbert A, Harrison R et al (2014) The Angelina Jolie effect: how high celebrity profile can have a major impact on provision of cancer related services. Breast Cancer Res 16(5):442CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Medicine Io: roundtable on translating genomic-based research for health. Institute of Medicine, Washington, DC, 2008 Medicine Io: roundtable on translating genomic-based research for health. Institute of Medicine, Washington, DC, 2008
25.
Zurück zum Zitat Rogers EM (1995) Diffusion of innovations, 4th edn. Free Press, New York Rogers EM (1995) Diffusion of innovations, 4th edn. Free Press, New York
26.
Zurück zum Zitat Cook-Deegan R, Niehaus A (2014) After myriad: genetic testing in the wake of recent supreme court decisions about gene patents. Curr Genet Med Rep 2(4):223–241CrossRefPubMedPubMedCentral Cook-Deegan R, Niehaus A (2014) After myriad: genetic testing in the wake of recent supreme court decisions about gene patents. Curr Genet Med Rep 2(4):223–241CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Bellcross CA, Kolor K, Goddard KA, Coates RJ, Reyes M, Khoury MJ (2011) Awareness and utilization of BRCA1/2 testing among U.S. primary care physicians. Am J Prev Med 40(1):61–66CrossRefPubMed Bellcross CA, Kolor K, Goddard KA, Coates RJ, Reyes M, Khoury MJ (2011) Awareness and utilization of BRCA1/2 testing among U.S. primary care physicians. Am J Prev Med 40(1):61–66CrossRefPubMed
28.
Zurück zum Zitat Roberts MC, Dusetzina SB (2017) The effect of a celebrity health disclosure on demand for health care: trends in BRCA testing and subsequent health services use. J Commun Genet 8(2):141–146CrossRef Roberts MC, Dusetzina SB (2017) The effect of a celebrity health disclosure on demand for health care: trends in BRCA testing and subsequent health services use. J Commun Genet 8(2):141–146CrossRef
29.
Zurück zum Zitat Armstrong J, Toscano M, Kotchko N et al (2015) Utilization and outcomes of brca genetic testing and counseling in a national commercially insured population: the about study. JAMA Oncol 1(9):1251–1260CrossRefPubMed Armstrong J, Toscano M, Kotchko N et al (2015) Utilization and outcomes of brca genetic testing and counseling in a national commercially insured population: the about study. JAMA Oncol 1(9):1251–1260CrossRefPubMed
30.
31.
Zurück zum Zitat Dean M, Boland J, Yeager M, Im KM, Garland L, Rodriguez-Herrera M, Perez M, Mitchell J, Roberson D, Jones K et al: Addressing health disparities in Hispanic breast cancer: accurate and inexpensive sequencing of BRCA1 and BRCA2. GigaScience 2015, 4(1):1–13CrossRef Dean M, Boland J, Yeager M, Im KM, Garland L, Rodriguez-Herrera M, Perez M, Mitchell J, Roberson D, Jones K et al: Addressing health disparities in Hispanic breast cancer: accurate and inexpensive sequencing of BRCA1 and BRCA2. GigaScience 2015, 4(1):1–13CrossRef
33.
Zurück zum Zitat Chen Z, Kolor K, Grosse SD, Rodriguez JL, Lynch JA, Green RF, Dotson WD, Bowen MS, Khoury MJ: Trends in utilization and costs of BRCA testing among women aged 18–64 years in the United States, 2003–2014. Genet Med 2017 Chen Z, Kolor K, Grosse SD, Rodriguez JL, Lynch JA, Green RF, Dotson WD, Bowen MS, Khoury MJ: Trends in utilization and costs of BRCA testing among women aged 18–64 years in the United States, 2003–2014. Genet Med 2017
34.
Zurück zum Zitat Hoskins PJ, Gotlieb WH (2017) Missed therapeutic and prevention opportunities in women with BRCA-mutated epithelial ovarian cancer and their families due to low referral rates for genetic counseling and BRCA testing: a review of the literature. CA 67(6):493–506 Hoskins PJ, Gotlieb WH (2017) Missed therapeutic and prevention opportunities in women with BRCA-mutated epithelial ovarian cancer and their families due to low referral rates for genetic counseling and BRCA testing: a review of the literature. CA 67(6):493–506
Metadaten
Titel
Concordance with BRCA1/2 testing guidelines among women in The Health of Women (HOW) Study®
verfasst von
Michelle I. Silver
William Klein
Goli Samimi
Lori Minasian
Jennifer Loud
Megan C. Roberts
Publikationsdatum
09.11.2018
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 3/2019
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-018-5035-0

Weitere Artikel der Ausgabe 3/2019

Breast Cancer Research and Treatment 3/2019 Zur Ausgabe

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

03.05.2024 Mammakarzinom Nachrichten

Wenn bei Mammakarzinomen durch eine neoadjuvante Chemotherapie ein Downstaging von nodal-positiv zu nodal-negativ gelingt, scheint es auch ohne Axilladissektion nur selten zu axillären Rezidiven zu kommen.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

02.05.2024 Prostatakarzinom Nachrichten

Eine adjuvante Radiotherapie nach radikaler Prostata-Op. bringt den Betroffenen wahrscheinlich keinen Vorteil. Im Gegenteil: Durch die Bestrahlung steigt offenbar das Risiko für Harn- und Stuhlinkontinenz.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärzte und Psychotherapeuten.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.